All the news Showing 10 of 99 articles from: Treatment outcomesGet an RSS feed of these articles Show All news infohep newsEditors' picks from other sources Minimal monitoring of hepatitis C treatment is safe and effective Keith Alcorn / 17 November 2020 Hepatitis C treatment with no monitoring visits during treatment is safe and leads to a high cure rate, an international study reported on Monday at the online AASLD Liver Meeting. The study was ... 13% of HIV-positive Europeans who are cured of hepatitis C are reinfected Liz Highleyman / 05 August 2019 More than one in ten HIV-positive people in the large EuroSIDA cohort who were cured of hepatitis C were reinfected within two years, according to a report last month at ... Hepatitis C does not raise risk of heart disease or cancers in people with HIV Keith Alcorn / 18 July 2019 Hepatitis C co-infection does not increase the risk of cardiovascular disease or non-AIDS cancers in people with HIV, an analysis of the large EuroSIDA cohort published in Clinical Infectious Diseases has found. ... Risk of Parkinson's disease lower in people treated for hepatitis C Keith Alcorn / 18 June 2019 People with hepatitis C who received interferon-based treatment were less likely to develop Parkinson’s disease, a large study from Taiwan has concluded. The results, published in JAMA Neurology, add to the evidence ... Pangenotypic hepatitis C drug combinations curing almost all people who complete treatment, real-world studies show Keith Alcorn / 12 April 2019 Once-daily combination pills that can treat all genotypes of hepatitis C infection are curing almost everyone who completes a course of treatment, and drop-out rates during treatment are low, large 'real-world' cohort ... Hepatitis C deaths fall by 16 per cent between 2015 and 2017 Public Health England / 09 April 2019 Hepatitis C treatment appears safe and effective for pregnant women Liz Highleyman / 20 March 2019 Treatment with sofosbuvir/ledipasvir (Harvoni) was well tolerated and cured all pregnant women with hepatitis C virus (HCV), according to a study presented at the Conference on Retroviruses and Opportunistic Infections (CROI 2019) ... 7% of patients coinfected with HCV and HIV fail DAA therapy Healio / 14 March 2019 DAA treatment reduces the risk of death and liver cancer in France Keith Alcorn / 12 February 2019 Treatment with direct-acting antivirals (DAAs) reduced the risk of death, liver cancer and death from liver-related causes in French people with hepatitis C, according to results of one of the largest studies ... Generic DAAs achieve excellent cure rates in Egypt matching those of branded drugs at a fraction of the cost Michael Carter / 01 February 2019 Generic direct-acting antivirals (DAAs) are just as effective and safe as their branded equivalents for the treatment of chronic hepatitis C virus (HCV) infection, according to Egyptian research published in Liver International. Generics achieved ... ← First12345...10Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Noticeboard Email bulletins News feeds